title: [Allogeneic stem-cell transplantation in adults 1985-2012: results and development].
abstract: BACKGROUND
  Allogeneic stem cell transplantation (ASCT) has been a treatment option for patients with serious diseases of the blood and haematopoietic organs in Norway since 1985. Such treatment is potentially curative for selected patients who have a relatively short predicted survival with other treatment modalities. This article summarises the experience and results from ASCT at Oslo University Hospital Rikshospitalet.
  
  
  METHODS
  The study included all of the 734 adult patients who had undergone allogeneic stem cell transplantation at the Department of Haematology, Rikshospitalet, later Oslo University Hospital Rikshospitalet, from November 1985 to October 2012.
  
  
  RESULTS
  At the time of analysis, altogether 384 patients were alive, and the five and ten-year survival rates were 54% and 48% respectively. The median follow-up time was six years. A total of 339 patients (46%) had developed acute graft-versus-host disease (GvHD), and 250 (73%) of these had GvHD ≥ grade II. Altogether 280 out of 602 patients who lived ≥ 100 days after the transplantation (46.5%) developed chronic GvHD. The most frequent causes of death included recurrence of the initial disease in 116 patients (33.1 %), multi organ failure after transplantation in 88 patients (25.4%), infections in 54 patients (16%) and GvHD in 33 patients (9.4%).
  
  
  CONCLUSIONS
  ASCT is a treatment option with a curative potential for patients with serious haematological diseases when other forms of treatment provide few prospects for recovery. The total survival rate in our study is in accordance with international results for the same time period, and the indications have consistently been in line with what is accepted internationally.
authors.affiliation: Avdeling for blodsykdommer Oslo universitetssykehus, Rikshospitalet.
authors.forename: Magnus Andreas Rognlien
authors.initials: MA
authors.lastname: Husøy
authors.affiliation: Avdeling for blodsykdommer Oslo universitetssykehus, Rikshospitalet.
authors.forename: Lorentz
authors.initials: L
authors.lastname: Brinch
authors.affiliation: Avdeling for blodsykdommer Oslo universitetssykehus, Rikshospitalet og Institutt for klinisk medisin Universitetet i Oslo.
authors.forename: Geir E
authors.initials: GE
authors.lastname: Tjønnfjord
authors.affiliation: Avdeling for blodsykdommer Oslo universitetssykehus, Rikshospitalet.
authors.forename: Tobias
authors.initials: T
authors.lastname: Gedde-Dahl
authors.affiliation: Avdeling for blodsykdommer Oslo universitetssykehus, Rikshospitalet.
authors.forename: Dag
authors.initials: D
authors.lastname: Heldal
authors.affiliation: Avdeling for blodsykdommer Oslo universitetssykehus, Rikshospitalet.
authors.forename: Pål André
authors.initials: PA
authors.lastname: Holme
authors.affiliation: Avdeling for blodsykdommer Oslo universitetssykehus, Rikshospitalet.
authors.forename: Ingunn
authors.initials: I
authors.lastname: Dybedal
authors.affiliation: Avdeling for kreftbehandling Oslo universitetssykehus, Rikshospitalet.
authors.forename: Arne
authors.initials: A
authors.lastname: Kolstad
authors.affiliation: Avdeling for immunlogi og transfusjonsmedisin Oslo universitetssykehus, Ullevål.
authors.forename: Çiğdem Akalin
authors.initials: ÇA
authors.lastname: Akkök
authors.affiliation: Avdeling for mikrobiologi Oslo universitetssykehus, Rikshospitalet og Institutt for klinisk medisin Universitetet i Oslo.
authors.forename: Halvor
authors.initials: H
authors.lastname: Rollag
authors.affiliation: Avdeling for mikrobiologi Oslo universitetssykehus, Rikshospitalet og Institutt for klinisk medisin Universitetet i Oslo.
authors.forename: Peter
authors.initials: P
authors.lastname: Gaustad
authors.affiliation: Avdeling for farmakologi Oslo universitetssykehus, Rikshospitalet og Farmasøytisk institutt Universitetet i Oslo.
authors.forename: Stein
authors.initials: S
authors.lastname: Bergan
authors.affiliation: Avdeling for immunlogi og transfusjonsmedisin Oslo universitetssykehus, Rikshospitalet.
authors.forename: Torstein
authors.initials: T
authors.lastname: Egeland
authors.affiliation: Seksjon for celleterapi Avdeling for kreftbehandling Oslo universitetssykehus, Radiumhospitalet.
authors.forename: Dag
authors.initials: D
authors.lastname: Josefsen
authors.affiliation: Seksjon for celleterapi Avdeling for kreftbehandling Oslo universitetssykehus, Radiumhospitalet.
authors.forename: Gunnar
authors.initials: G
authors.lastname: Kvalheim
authors.affiliation: Avdeling for blodsykdommer Oslo universitetssykehus, Rikshospitalet.
authors.forename: Yngvar
authors.initials: Y
authors.lastname: Fløisand
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D002423:Cause of Death; D005260:Female; D005500:Follow-Up Studies; D006086:Graft vs Host Disease / Q000453:epidemiology; D018380:Hematopoietic Stem Cell Transplantation / Q000009:adverse effects / Q000401:mortality / Q000706:statistics & numerical data; D006785:Hospitals, University; D006801:Humans; D007945:Leukemia, Lymphoid / Q000453:epidemiology / Q000628:therapy; D007951:Leukemia, Myeloid / Q000453:epidemiology / Q000628:therapy; D008297:Male; D008875:Middle Aged; D009664:Norway; D011183:Postoperative Complications / Q000453:epidemiology; D015996:Survival Rate; D014184:Transplantation, Homologous / Q000009:adverse effects / Q000401:mortality / Q000706:statistics & numerical data